Clinical trials: Breast Cancer, Metastatic Breast Cancer
Metastatic Breast Cancer
Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons
Primary Objectives Assess ultrastructure changes in dermal myelinated nerves of patients who receive ixabepilone chemotherapy Detailed characterization of peripheral neuropathy in patients who receive ixabepilone Secondary…
- Trial name
- NCT00627978
- Testing
- ixabepilone
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Weill Medical College of Cornell University
Cancer
Lapatinib in Combination With Vinorelbine
This is a Multicenter, Open-Label, Phase II Study of lapatinib in Combination with Vinorelbine in women with documented evidence of HER2/neu positive breast cancer which is metastatic or recurrent and with or without prior…
- Trial name
- NCT01128543
- Testing
- lapatinib and Vinorelbine
- Where
- 8 sites in Turkey (Türkiye)
- Volunteers
- 29 people
- Sponsor
- GlaxoSmithKline
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
This phase I/Ib trial tests the safety, side effects, best dose, and effectiveness of ASTX660 (tolinapant) in combination with eribulin mesylate (eribulin) in treating patients with triple negative breast cancer that cannot be…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced HER2-Negative Breast Carcinoma
- Trial name
- NCT06590558
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Sponsor
- National Cancer Institute (NCI)
Prostatic Neoplasms, Breast Cancer
Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)
The primary objective is: To determine the efficacy of modafinil in the reduction of fatigue in patients with metastatic breast or prostate cancer undergoing docetaxel-based chemotherapy The secondary objectives are: To determine…
- Trial name
- NCT00917748
- Testing
- DOCETAXEL(XRP6976) + MODAFINIL, Modafinil
- Where
- Australia
- Volunteers
- 84 people
- Sponsor
- Sanofi
Breast Cancer
AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy
The purpose of this study is to look at the effects that the study drug (OPC) has on AGE levels in patients with ER+ metastatic breast cancer.
- Trial name
- NCT03092635
- Testing
- OPC
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medical University of South Carolina
Breast Cancer, Adenocarcinoma
Study of MDX-010 in Stage IV Breast Cancer
This Phase II study is designed to treat patients who have been diagnosed with Stage IV Breast Cancer, which has progressed despite treatment with primary therapies, including hormonal therapy, chemotherapy, and antibody therapy.
- Trial name
- NCT00083278
- Testing
- MDX-010
- Where
- 14 sites in United States
- Volunteers
- 33 people
- Sponsor
- Bristol-Myers Squibb
CTIT-Chemotherapy Induced Thrombocytopenia, Breast Cancer
Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study
The title of this study is: A two-cohort, single-arm, exploratory Phase II clinical study on the primary/secondary prevention ADC drug of heltrombopag for thrombocytopenia caused by breast cancer.
- Trial name
- NCT07243418
- Testing
- herombopag olamine tablets
- Volunteers
- 72 people
- Sponsor
- Fujian Cancer Hospital
Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers
The study aims at exploring the potential benefit of a PARP-inhibitor, Niraparib, in metastatic breast cancer developing in germline-PALB2 mutations carriers.
- Trial name
- PALB2-PARPi-01 (NCT05232006)
- Testing
- Niraparib
- Volunteers
- 12 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced Breast Cancer Brain Metastasis
A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis.
A prospective, multicenter, observational cohort study to evaluate the efficacy and safety of a novel anti-tumor drug as a radiosensitizer in patients with advanced breast cancer brain metastasis.
- Trial name
- NCT06839547
- Testing
- Radiotherapy + Novel Anti-tumor Drug
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Metastatic Breast Cancer
Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR)
A biopsy of a tumor lesion (breast or other localisation) will be performed for processing to establish avatars (patient-derived organoids -PDO).
- Trial name
- AVATAR (NCT06459791)
- Testing
- Biopsy
- Where
- 3 sites in France
- Volunteers
- 110 people
- Sponsor
- Institut Curie
Metastatic Breast Cancer
Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca
The purpose of this study is to determine the response rate, that is the % of patients with non-progression of their metastatic breast cancer after 4 months on treatment that was selected by molecular testing and proteomics.
- Trial name
- Side-Out (NCT01074814)
- Testing
- Approved therapy will be assigned based on molecular profile and RPMA results
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Translational Drug Development
Breast Cancer
Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)
NK (Natural Killer) cells are important in the fight against tumor, especially for the control of cancer metastasis. The purpose of this prospective study is to evaluate the impact on lymphocytes NK functions and development of…
- Trial name
- RAPANK (NCT02536625)
- Testing
- prospective study
- Where
- 2 sites in France
- Volunteers
- 62 people
- Sponsor
- Centre Leon Berard
Breast Cancer
Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer
The purpose of this study is to evaluate and compare the clinical benefit and safety of treatment with enzalutamide in combination with paclitaxel chemotherapy or as monotherapy versus placebo with paclitaxel in patients with…
- Trial name
- ENDEAR (NCT02929576)
- Testing
- Enzalutamide, Paclitaxel
- Where
- 6 sites in United States
- Sponsor
- Pfizer
Breast Cancer
Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer
This study is aim to evaluate the efficacy and safety of bicalutamide and aromatase inhibitor in ER(+)/AR(+)/HER2(-) metastatic breast cancer patients who have disease progression after treatment of an aromatase inhibitor.
- Trial name
- BETTER (NCT02910050)
- Testing
- Bicalutamide, Aromatase Inhibitor
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Xu fei
Breast Cancer
Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NCT00004925
- Testing
- trastuzumab, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Neoplasms
Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)
The purpose of this study is to evaluate the safety and efficacy of pegylated liposomal doxorubicin (Caelyx) in elderly patients who are to receive first-line chemotherapy for metastatic or locally advanced breast cancer, not…
- Trial name
- NCT00604968
- Testing
- Caelyx (pegylated liposomal doxorubicin; SCH 200746)
- Volunteers
- 25 people
- Sponsor
- Merck Sharp & Dohme LLC
HER2 Positive Metastatic Breast Cancer
Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
This study plans to explore the efficacy and safety of chemotherapy combined with inetetamab and PD-1 inhibitors in HER2 positive advanced breast cancer who failed to receive trastuzumab and TKIs, and explore the dominant…
- Trial name
- NCT04681287
- Testing
- inetetamab and PD-1 inhibitor combined with chemotherapy.
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer, Drug-induced Nausea and Vomiting
Acupressure in Treating Nausea in Women Receiving Combination Chemotherapy for Breast Cancer
RATIONALE: Acupressure may help to reduce or prevent nausea in patients who are undergoing chemotherapy. It is not yet known whether acupressure plus standard care for nausea is more effective than standard care alone for nausea…
- Trial name
- NCT00046865
- Testing
- acupressure therapy, management of therapy complications, nausea and vomiting therapy
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Breast Cancer, Recurrent Breast Cancer
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
This research study is a way of gaining new knowledge about the combination of Taselisib with other drugs in the treatment of metastatic breast cancer.
- Trial name
- NCT02390427
- Testing
- Taselisib, Trastuzumab emtansine, Pertuzumab
- Where
- 3 sites in United States
- Volunteers
- 68 people
- Sponsor
- Nancy Lin, MD
Metastatic Breast Cancer
A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer
The purpose of this study is to determine if the addition of metformin to standard chemotherapy improves progression free survival in women with metastatic breast cancer.
- Trial name
- NCT01310231
- Testing
- Metformin
- Where
- 5 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Ozmosis Research Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.